By Fineline Cube 
German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with Re-Vana Therapeutics, a US and UK-based company specializing in ophthalmic therapeutics and drug delivery. The partnership focuses on developing first-in-class, long-acting sustained release therapies for ocular diseases.
Collaboration Details
Under the agreement, Boehringer Ingelheim plans to add up to three new projects annually across various therapeutic areas. Both companies will collaborate on the feasibility and development of Re-Vana’s sustained release programs. Boehringer Ingelheim will take exclusive responsibility for clinical development, regulatory approval, and global commercialization.
Financial Terms
The agreement grants Boehringer Ingelheim exclusive rights to specific targets. Re-Vana will receive an upfront payment, along with development, regulatory, and sales milestone payments. The potential aggregate deal value for the first three targets exceeds $1 billion, in addition to sales royalties.-Fineline Info & Tech